Monte Rosa Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GLUE Nasdaq 2830 www.monterosatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - Jun 10th, 2025 5:00 am
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet - Jun 9th, 2025 7:55 am
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - May 28th, 2025 5:00 am
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - May 8th, 2025 6:25 am
Monte Rosa Therapeutics: Q1 Earnings Snapshot - May 8th, 2025 5:21 am
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates - May 8th, 2025 5:00 am
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer - Apr 28th, 2025 5:00 am
Monte Rosa Therapeutics Insider Ups Holding During Year - Apr 22nd, 2025 11:35 am
Mixed data results for two Monte Rosa molecular glue degraders - Mar 21st, 2025 7:33 am
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates - Mar 20th, 2025 8:35 am
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - Mar 20th, 2025 5:00 am
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - Mar 11th, 2025 5:00 am
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Mar 7th, 2025 6:22 am
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Feb 24th, 2025 5:00 am
Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans - Jan 31st, 2025 9:33 am
Monte Rosa Therapeutics provide corporate update, key milestones 2025 - Jan 11th, 2025 5:27 am
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - Jan 10th, 2025 5:00 am
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 6th, 2025 5:00 am
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Dec 13th, 2024 5:00 am
Monte Rosa Closes Global License Agreement With Novartis - Dec 11th, 2024 5:45 am